ISRCTN32507927
Completed
未知
The chronic care for age-related macular degeneration study (CHARMED): A randomised controlled trial
niversity Hospital Zurich (Universitaetsspital Zurich) (Switzerland)0 sites352 target enrollmentMarch 17, 2011
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Age-related macular degeneration (wet AMD)
- Sponsor
- niversity Hospital Zurich (Universitaetsspital Zurich) (Switzerland)
- Enrollment
- 352
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female patients with neovascular age\-related macular degeneration (wet AMD)
- •2\. Eligible for a therapy with anti\-angiogenic drug
- •3\. Visual acuity less than equal to 0\.05 (assessed by Early Treatment Diabetic Retinopathy Study ETDRS charts)
- •4\. Age more than 50 years
- •5\. Written informed consent given before any study related procedure is performed
Exclusion Criteria
- •1\. Serious general or psychological illness (advanced malignant tumours, serious depressive episodes, evidence of dementia)
- •2\. Insufficient language skills (informed consent, patient information and questionnaires will be provided in German and French)
- •3\. Patients with any invasive medical treatment for wet AMD in the past
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
The effect of saffron supplementation on vision in patients with early dry age-related macular degeneratioACTRN12612000729820The University of Sydney100
Active, not recruiting
Phase 1
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2014-003132-39-FRBayer HealthCare AG268
Active, not recruiting
Phase 1
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2014-003132-39-GBBayer AG287
Active, not recruiting
Phase 1
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2014-003132-39-ESBayer HealthCare AG268
Active, not recruiting
Phase 1
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2014-003132-39-ITBAYER AG287